CTGF: Function, Role in Disease, and Therapeutic Use

Connective tissue growth factor, or CTGF (also called CCN2), is a small signaling protein that helps orchestrate how the body builds and repairs connective tissues, from cartilage and bone to skin and blood vessels. It is a 38-kilodalton, cysteine-rich protein made of four functional modules, and it influences an unusually wide range of biological processes, including wound healing, skeletal development, and blood vessel formation.¹ When CTGF stays active too long or at too high a level, though, it becomes a driver of fibrosis and other diseases, making it one of the most intensely studied therapeutic targets in fibrotic medicine.

How CTGF Works at the Molecular Level

CTGF does not act the way most growth factors do. Rather than binding a single dedicated receptor and flipping a clean on-or-off switch inside a cell, it functions more like a molecular matchmaker. One of its four modules contains a cysteine-rich domain similar to those found in chordin and other secreted proteins. Through that domain, CTGF directly binds major signaling molecules such as BMP-4 and TGF-beta 1, modulating how strongly those signals reach nearby cells.² In practice, this means CTGF amplifies or dampens the activity of other growth factors depending on the tissue context, rather than issuing its own standalone commands.

This co-factor behavior helps explain one of CTGF’s most confusing features: it promotes fibroblast growth, matrix production, and new blood vessel formation in concert with other molecules, but on its own it has limited independent activity.³ Think of it less as a lead actor and more as a director who coordinates an ensemble cast. It is the surrounding cast of signaling molecules that determines whether the outcome is healthy repair or destructive scarring.

CTGF Is Secreted as an Inactive Precursor

One of the more surprising discoveries about CTGF is that the full-length protein secreted by cells is biologically inert. The molecule is essentially locked in an inactive configuration by its own two N-terminal domains, acting as a built-in safety catch. For CTGF to become active, enzymes called matrix metalloproteinases must clip the protein, releasing a C-terminal fragment composed of its third and fourth domains. That fragment carries all of the protein’s biologically relevant signaling activity.⁴

The active fragment can also form pairs (homodimers) that are roughly twenty-fold more potent than the single-molecule form in triggering signaling cascades inside cells.⁴ This two-step activation system, clipping followed by pairing, gives the body fine-grained control over where and when CTGF exerts its effects. In healthy tissues such as the eye, abundant smaller CTGF fragments circulate with only trace amounts of the full-length protein, suggesting that controlled processing is the normal state of affairs.⁵

What Switches CTGF Production On

Two major inputs drive CTGF expression: chemical signals and physical forces. On the chemical side, TGF-beta is the best-known trigger. When TGF-beta activates its pathway inside a cell, Smad2 proteins and the transcriptional regulators YAP and TAZ move into the nucleus and cooperate with TEAD transcription factors to turn on CTGF production.⁶ Knocking down YAP by about 80 percent in kidney cells was enough to nearly abolish both baseline and TGF-beta-stimulated CTGF secretion, confirming that YAP is indispensable for CTGF synthesis.⁷

The physical side is equally important. Mechanical stress, the kind of force that tissues experience when they are stretched or compressed, is one of the strongest inducers of CTGF. In experiments on smooth-muscle cells, mechanical loading was required to sustain high-level CTGF expression; TGF-beta alone was not sufficient.⁸ Even the stiffness of the surface on which cells sit matters. Retinal cells grown on firmer substrates reached peak CTGF production earlier than cells on softer substrates, and the timing of that peak matched when YAP and TAZ migrated into the cell nucleus.⁹ This mechano-sensitivity has practical implications: in stiffened fibrotic tissue, the very rigidity of the scar feeds back to sustain CTGF production, potentially creating a self-perpetuating cycle of scarring.

CTGF in Skeletal Development

During embryonic growth and childhood, CTGF plays a starring role in building the skeleton. Most bones form through a process called endochondral ossification, where a cartilage template is gradually replaced by mineralized bone. CTGF is produced by a specific population of cartilage cells and acts on all the surrounding mesenchymal cells inside the developing bone to coordinate this transformation.¹⁰

Mice engineered to lack CTGF entirely illustrate just how critical it is. These knockout animals develop skeletal abnormalities because their cartilage cells fail to proliferate normally and their extracellular matrix composition goes awry. The growth plates in their bones expand abnormally, and the conversion of cartilage to bone is impaired. Part of the reason is that without CTGF, levels of vascular endothelial growth factor (VEGF) drop in the growth plate, cutting off the blood vessel invasion that bone formation depends on.¹¹ CTGF, in other words, is not just promoting cartilage growth; it is coupling cartilage remodeling to the blood supply, ensuring one does not outpace the other.

Wound Healing and the Line Between Repair and Scarring

After an injury, CTGF appears transiently. Fibroblasts and mesenchymal stem cells in the wound ramp up CTGF expression during the first days of tissue repair, promoting the formation of granulation tissue, the provisional scaffold that fills a wound before mature tissue replaces it. When researchers blocked CTGF during this early phase using antibodies, the resulting granulation tissue was sparser, less organized, and less vascular.¹² A similar transient burst of CTGF was confirmed in early-phase human burn wounds, reinforcing the idea that the protein plays a genuine pro-repair role when it is expressed briefly and then turned off.¹²

Problems arise when CTGF fails to quiet down. Prolonged administration of exogenous CTGF for more than fifteen days in animal wound models led to fibroblast overgrowth and excessive collagen deposition, hallmarks of scarring rather than healthy repair.¹² This time-dependent switch, helpful early, harmful late, is central to understanding every disease CTGF participates in. The difference between healing and fibrosis often comes down to whether CTGF expression resolves on schedule.

Fibrotic Disease Across Organs

Fibrosis, the excessive accumulation of scar tissue in an organ, is a process in which CTGF is consistently overexpressed. Because the protein acts broadly, its involvement spans nearly every organ system where fibrosis occurs.

Lung

In idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease, CTGF is upregulated in lung cells and contributes to the accumulation of pathological extracellular matrix.¹³ Recent research has linked CTGF in IPF to abnormal metabolic reprogramming associated with cellular aging, suggesting the protein does more than simply promote collagen deposition; it may help sustain the senescent cell populations that maintain the fibrotic environment.

Liver

In the liver, CTGF is a major player in the activation of hepatic stellate cells, the cells responsible for producing scar tissue during chronic liver injury. CTGF promotes these stellate cells to transform into myofibroblasts, the collagen-producing workhorses of fibrosis.¹⁴ Blocking CTGF with small interfering RNA in a rat model of chemically induced liver fibrosis prevented the disease from progressing, providing strong preclinical evidence that CTGF is not merely a bystander but a causal driver.¹⁵ Separate work using the Src kinase inhibitor saracatinib showed that blocking TGF-beta-induced CTGF expression in liver cells also reduced collagen and other fibrosis markers in mice.¹⁶

Kidney

Diabetic nephropathy, one of the leading causes of kidney failure worldwide, also involves CTGF. In diabetic rat kidneys, CTGF expression in the outer kidney tissue roughly doubled compared with healthy controls.¹⁷ The downstream effects are worth noting for their complexity: CTGF on its own increased fibronectin production in kidney tubular cells by about half, but it only boosted collagen production when combined with insulin-like growth factor, producing a more-than-additive spike in collagen III messenger RNA.¹⁷ This synergy with other growth factors echoes the co-factor behavior seen in the protein’s basic biology and complicates any therapeutic strategy that targets CTGF alone.

CTGF and the Heart After a Heart Attack

The role of CTGF in the heart offers a revealing paradox. After a heart attack, CTGF rises in the damaged tissue. Treating mice with a monoclonal antibody that neutralized CTGF reduced fibrosis in the non-infarcted portions of the heart wall, the remote zones that scar up in the weeks after a heart attack and contribute to progressive heart failure.¹⁸ By that logic, CTGF looks like a straightforward villain worth blocking.

Yet a separate study engineered mice to overexpress CTGF specifically in heart muscle. Those mice actually fared better after a heart attack: they developed smaller scars, less cardiac enlargement, less loss of pumping function, and substantially lower mortality.¹⁹ In a small cohort of human heart attack patients, rising serum CTGF levels after the event were associated with smaller infarcts and better heart function a year later.¹⁹ This apparent contradiction likely reflects the difference between CTGF produced locally by heart muscle cells, which may modulate inflammation and protect tissue, and CTGF that drives excess scar deposition from surrounding fibroblasts. The takeaway for drug development is sobering: blanket suppression of CTGF in the heart could remove a protective signal alongside the harmful one.

CTGF in the Eye

Diabetic retinopathy provides one of the clearest illustrations of how CTGF interacts with VEGF. In the early, pre-clinical stages of the disease, CTGF contributes to thickening of retinal capillary basement membranes and loss of the pericyte cells that stabilize blood vessels.²⁰ In the later proliferative stage, the balance between VEGF and CTGF appears to determine whether the retina is forming new (leaky, fragile) blood vessels or laying down fibrous scar tissue. Vitreous fluid analysis in patients with proliferative diabetic retinopathy showed that CTGF levels tracked with the degree of fibrosis, while VEGF levels tracked with the degree of abnormal new vessel growth.²¹

This has a clinically important wrinkle. Anti-VEGF injections, now standard treatment for proliferative diabetic retinopathy, can shift the balance toward CTGF dominance and inadvertently promote fibrosis. In patient case studies, a transition from new blood vessel growth to advancing pre-retinal fibrosis was observed after anti-VEGF treatment followed by laser therapy.²¹ This “angio-fibrotic switch” is a practical concern for ophthalmologists and a reminder that CTGF and VEGF are not independent targets but counterweights in a seesaw.

CTGF and Cancer

CTGF’s role in cancer is context-dependent and still being worked out. In prostate cancer, stromal cells engineered to express CTGF produced tumors with roughly 72 percent more blood vessels and about 35 percent greater tumor mass than controls.²² The protein here is acting through its pro-angiogenic and matrix-remodeling functions, essentially making the tumor’s neighborhood more hospitable. Meanwhile, the convergence of YAP/TAZ and TGF-beta signaling that drives CTGF expression has been linked to pro-tumorigenic gene programs in breast cancer cells.⁶ Whether CTGF itself is a viable oncology target or merely a downstream marker of dangerous upstream signaling remains an open question.

CTGF as a Biomarker

Because CTGF levels change in response to tissue injury and remodeling, measuring the protein in blood or urine has attracted interest as a way to detect or predict disease. In one of the more counterintuitive findings, data from the Framingham Heart Study showed that lower baseline urinary CTGF concentrations were associated with a higher risk of developing chronic kidney disease stage 3. Each standard-deviation increase in urinary CTGF was associated with about a 67 percent reduction in odds of incident kidney disease, after adjusting for established risk factors.²³ A similar trend was observed in a separate validation cohort, particularly in people without diabetes.²³

This inverse relationship is puzzling at first glance, given CTGF’s reputation as a fibrosis promoter. One possibility is that normal levels of urinary CTGF reflect healthy tissue turnover and maintenance, and that low levels indicate a kidney that is already quietly losing functional capacity. Whatever the mechanism, it suggests CTGF’s biomarker utility will not follow a simple “more is worse” pattern and will require disease-specific reference ranges.

Therapeutic Approaches Targeting CTGF

The most clinically advanced anti-CTGF therapy has been pamrevlumab, a fully human monoclonal antibody designed to neutralize CTGF in the bloodstream. In a phase 2 trial for IPF (the PRAISE trial), pamrevlumab reduced the decline in lung function by about 60 percent over 48 weeks compared with placebo, and only 10 percent of pamrevlumab-treated patients experienced disease progression versus roughly 31 percent in the placebo group.²⁴ These results generated considerable excitement.

The follow-up phase 3 trial, ZEPHYRUS-1, did not replicate those findings. Over the same 48-week period, the difference in lung function decline between pamrevlumab and placebo was not statistically significant, and none of the secondary or exploratory outcomes showed a benefit either.²⁵ The trial formally failed its primary endpoint. The reasons for the disconnect between phase 2 and phase 3 are still debated, but the outcome is a reminder that CTGF, which works as a co-factor rather than a standalone driver, may not be sufficient as a solo target. Blocking just one node in a web of interconnected signals sometimes works in a small trial and falls apart when tested at scale.

Antisense Approaches for Scarring

A different strategy has shown more consistent results in a narrower application: using short synthetic DNA fragments called antisense oligonucleotides to silence CTGF messenger RNA directly at the wound site. In a rabbit ear model of hypertrophic scarring, antisense treatment had no measurable effect on early wound closure but significantly reduced subsequent scar formation. The treated scars had far fewer myofibroblasts, the contractile cells that generate the mechanical tension in raised, tight scars, along with lower collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) expression.²⁶

A randomized, double-blind human trial of one such antisense compound (EXC 001) went further. Patients undergoing scar revision surgery received either EXC 001 or placebo injections at the wound site. The treated scars were rated significantly less severe by expert panels and physicians at both 12 and 24 weeks after surgery.²⁷ The fact that early wound healing was unaffected aligns neatly with the biology: CTGF’s early, transient role in wound repair is driven by a brief pulse that the antisense treatment apparently does not disrupt, while its later, sustained role in excessive scarring is the part that gets silenced.

Evolutionary Conservation

CTGF is not a recent invention. Comparative genomic studies have found CCN family homologs across a wide range of animal species, with highly conserved structural features in their protein modules.²⁸ In zebrafish, the CTGF gene has been shown to play a role in notochord development that parallels what has been observed in mice, consistent with the idea that the mechanisms governing vertebral development are deeply shared among vertebrates.²⁹ This conservation is relevant beyond academic curiosity: it means findings from animal models of CTGF function are likely to translate, at least directionally, to human biology, and it underscores that the protein’s core toolkit of tissue-building functions is hundreds of millions of years old.

Why Targeting CTGF Remains Difficult

The recurring theme across all of CTGF biology is context dependence. The same molecule is needed for skeletal growth, early wound repair, and apparently normal kidney maintenance, but becomes damaging when it persists at high levels in the wrong place or time. It acts through partnerships with other growth factors rather than through a clean, druggable pathway of its own. Its proteolytic activation adds another layer: a drug that blocks the full-length protein might have little effect if the active fragments are already circulating, while a drug that blocks the fragments might interfere with normal tissue maintenance.

The cardiac data illustrate the dilemma most sharply. Blocking CTGF in the fibroblasts around a heart attack scar reduces harmful fibrosis, but CTGF produced by the heart muscle cells themselves appears protective. A systemic antibody cannot distinguish between the two sources. Future therapies may need to be delivered locally, like the antisense oligonucleotides injected into surgical wounds, or designed to target specific CTGF fragments or specific upstream regulatory nodes like YAP/TAZ rather than the protein itself. Whether that level of precision is achievable at a clinically useful scale is the central open question in the field.

1
PubMed Central. The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis
2
PubMed Central. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta
3
Cytokine & Growth Factor Reviews. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis – Section: Biological function of CTGF/CCN2
4
PubMed Central. Connective tissue growth factor (CCN2) is a matricellular preproprotein controlled by proteolytic activation
5
PubMed Central. Proteolytic processing of connective tissue growth factor in normal ocular tissues and during corneal wound healing
6
PubMed Central. The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells
7
Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. Inhibitors of oxygen sensing prolyl hydroxylases regulate nuclear localization of the transcription factors Smad2 and YAP/TAZ involved in CTGF synthesis
8
PubMed. Mechanical stress is required for high-level expression of connective tissue growth factor
9
PubMed Central. Substrate Stiffness Influences the Time Dependence of CTGF Protein Expression in Müller Cells
10
PubMed. Role of CCN2/CTGF/Hcs24 in bone growth
11
PubMed Central. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development
12
PubMed Central. A physiological role for connective tissue growth factor in early wound healing
13
PubMed Central. Connective Tissue Growth Factor in Idiopathic Pulmonary Fibrosis: Breaking the Bridge
14
PubMed Central. Role of CTGF gene promoter methylation in the development of hepatic fibrosis
15
PubMed. Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo
16
PubMed Central. Src Inhibition Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation and Decreasing Connetive Tissue Growth Factor
17
Kidney International. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy
18
PubMed Central. Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction
19
PubMed Central. Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction
20
PubMed. The role of CTGF in diabetic retinopathy
21
PLoS ONE. The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
22
Cancer Research. Stromal Expression of Connective Tissue Growth Factor Promotes Angiogenesis and Prostate Cancer Tumorigenesis
23
PubMed Central. Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population
24
PubMed. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
25
JAMA. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
26
PubMed. Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo
27
PubMed. Anti-CTGF Oligonucleotide Reduces Severity of Postsurgical Hypertrophic Scars in a Randomized, Double-Blind, Within-Subject, Placebo-Controlled Study
28
PubMed Central. A Comparative Genomic and Phylogenetic Analysis of the Origin and Evolution of the CCN Gene Family
29
PubMed. The physiological role of CTGF/CCN2 in zebrafish notochond development and biological analysis of the proximal promoter region